Lexaria Bioscience Corp. — Capital/Financing Update 2009

Mar 4, 2009

8-K 1 lexaria8k030409.htm LEXARIA CORP. FORM 8-K html PUBLIC "-//IETF//DTD HTML//EN" CC Filed by Filing Services Canada Inc. 403-717-3898

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 4, 2009
LEXARIA CORP. (Exact name of registrant as specified in its charter)
Nevada (State or other jurisdiction of incorporation)	333-132134 (Commission File Number)	20-2000871 (IRS Employer Identification No.)
#604 – 700 West Pender Street, Vancouver, British Columbia, Canada V6C 1G8
Registrant's telephone number, including area code: (604) 602-1675
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

r

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

r

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

r

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

r

Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement

Item 3.02 Unregistered Sales of Equity Securities

On July 20, 2007, the Company had adapted a Stock Option Plan. Based on this original Stock Option Plan, on March 4, 2009, the Company has granted additional 800,000 stock options to its directors and consultants of the Company. The exercise price of the stock options is $0.12, which are vested immediately and expires July 20, 2011.

The following are the recipients and the options granted:

Christopher Bunka

400,000

Leonard MacMillan

200,000

Ken Brooks

100,000

Thomas Ihrke

50,000

Bal Bhullar

50,000

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit No.	Description
10.1	Stock Option Agreement, dated March 4, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 4, 2009

(Signature) Lexaria Corp. By: “ /s/ Chris Bunka” Chris Bunka President & CEO

C:\DOCUMENTS AND SETTINGS\BAL01\DESKTOP\2009 03 04 8K STOCK OPTION

EDGAR Validation Code: 6D0ACC16